Alnylam Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biopharmaceutical company built around RNA interference therapeutics. Recent Form 8-K reports furnish operating results and financial condition updates tied to product revenues from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, while other current reports disclose strategy updates, pipeline goals and clinical-program context.
The filing record also covers governance and capital structure matters, including the definitive proxy statement, executive compensation and equity-award disclosures, common stock registered on Nasdaq, a revolving credit facility and convertible senior note offering materials. These disclosures describe board oversight, compensation plans, financing arrangements, material corporate events and the formal exhibits supporting Alnylam's public-company reporting.
Alnylam Pharmaceuticals reported preliminary 2025 global net product revenues of approximately $2,987 million for its four marketed RNAi medicines, with fourth-quarter revenues of about $995 million. Alongside these early figures, the company introduced a new five-year strategy called “Alnylam 2030”, which is intended to guide its next phase of growth. Alnylam also shared its product and pipeline goals for 2026 and issued full-year 2026 combined net product revenue guidance, with final audited 2025 results to follow in February 2026.
Alnylam Pharmaceuticals director Stuart A. Arbuckle reported receiving a stock option award for 3,279 shares of the company’s common stock. The option, granted on January 5, 2026, has an exercise price of $397.83 per share and is structured as a right to buy shares in the future.
According to the filing, the option will vest in three equal installments, with one third of the shares vesting on each of the first, second and third anniversaries of the grant date. Following this grant, Arbuckle beneficially owns 3,279 stock options directly.
Alnylam Pharmaceuticals, Inc. director Stuart A. Arbuckle filed an initial insider ownership report. This Form 3 indicates that, as of the event date of 01/05/2026, he holds no securities beneficially owned in Alnylam. The filing confirms his role as a director and that the report is filed by one reporting person.
The document also includes a power of attorney, under which Brett Budzinski signed on Arbuckle's behalf. This filing is primarily administrative, establishing Arbuckle’s status as an insider without disclosing any equity ownership or transactions.
Alnylam Pharmaceuticals executive Kevin Fitzgerald, CSO & EVP, Head of Research, reported an insider transaction in ALNY common stock. On 11/17/2025, he exercised a stock option for 8,161 shares at an exercise price of $119.13 per share and acquired the underlying common stock.
That same day, he reported multiple open-market sales of ALNY common stock in separate small lots, including 8,168 shares at $449 per share and additional sales at weighted average prices spanning from $451.41 to $463.46 per share, each based on multiple individual trades. After these transactions, he reported beneficial ownership of 24,999 shares directly, 537 shares indirectly through a managed account, and 839 derivative securities remaining from the option award. The filing notes that these trades were made under a Rule 10b5-1(c) trading plan adopted on August 14, 2025.
Alnylam Pharmaceuticals reported strong Q3 2025 results, with total revenue of $1,249,026,000, up sharply year over year. Net product revenue reached $851,082,000, led by AMVUTTRA at $685,303,000, while collaboration revenue was $351,742,000, including a $300,000,000 Roche license milestone tied to the ZENITH Phase 3 initiation.
The company delivered income from operations of $367,982,000 and net income of $251,084,000, or $1.84 diluted EPS. Through nine months, operating cash flow was $360,525,000. The balance sheet showed cash and cash equivalents of $1,490,249,000 and marketable debt securities of $1,234,375,000, with convertible debt of $1,040,276,000. Accounts receivable increased to $964,768,000, reflecting higher sales and collaboration billings. Stockholders’ equity rose to $233,894,000, supported by profitability.
Within franchises, TTR therapies (AMVUTTRA and ONPATTRO) generated $724,378,000, and Rare (GIVLAARI and OXLUMO) delivered $126,704,000. At October 24, 2025, shares outstanding were 132,113,818.
Alnylam Pharmaceuticals (ALNY) announced its financial results for the quarter ended September 30, 2025. The company furnished a press release as Exhibit 99.1 with additional details.
The information is furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly stated.
Alnylam Pharmaceuticals (ALNY) officer Bryan Supran reported acquiring 13,026 shares of common stock via a restricted stock unit (RSU) grant on 10/01/2025. Each RSU represents the right to receive one share. The RSUs vest over three years, with one third vesting on each of the first, second, and third anniversaries of the grant date, contingent on continued service.
Following the reported transaction, 13,026 shares were beneficially owned on a direct basis.
Jeffrey V. Poulton, EVP and Chief Financial Officer of Alnylam Pharmaceuticals (ALNY), reported equity changes tied to performance-based stock units (PSUs) that vested following corporate milestones. On 10/01/2025 the reporting person received 3,108 shares from a 2/24/2021 PSU tranche and 4,644 shares from a 3/01/2024 PSU tranche after the issuer publicly reported initiation of a Phase 3 clinical study in a prevalent indication, as determined by the People, Culture and Compensation Committee.
The company automatically sold 3,821 shares on 10/02/2025 under a mandatory sell-to-cover provision to satisfy statutory tax withholding, at weighted-average prices ranging roughly from $446.19 to $456.09 across multiple transactions. After these transactions the reporting person beneficially owned 54,052 shares directly and 57 shares indirectly via a managed account; 57 additional shares were acquired under the issuer 401(k) matching program.
Alnylam Pharmaceuticals (ALNY) CEO Yvonne Greenstreet reported PSU-related share activity. On 10/01/2025, she acquired 3,860 and 14,252 shares at $0 upon PSU vesting tied to the initiation of a Phase 3 clinical study, as determined by the PC&C Committee. On 10/02/2025, the Company executed sell-to-cover transactions to satisfy tax withholding, with multiple weighted-average sales ranging from $446.53 to $457.64. Following these transactions, she held 65,409 shares directly and 407 shares indirectly by a managed account.
Alnylam Pharmaceuticals (ALNY) executive Tolga Tanguler, EVP and Chief Commercial Officer, reported equity activity on a Form 4. On 10/01/2025, 2,851 common shares were acquired at $0.00 upon vesting of performance-based stock units tied to the initiation of a Phase 3 clinical study, as determined by the Board’s People, Culture and Compensation Committee.
On 10/02/2025, shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy tax withholding, executed in multiple trades with weighted average prices ranging from $446.19 to $457.64. Following these transactions, the reporting person beneficially owned 27,438 shares directly.